Journal
LANCET
Volume 377, Issue 9778, Pages 1681-1692Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60516-3
Keywords
-
Categories
Funding
- Boehringer Ingelheim
- AstraZeneca
- Novartis
- Pfizer
- Sanofi-Aventis
- Otsuka Pharmaceutical
Ask authors/readers for more resources
Stroke is a major cause of death and disability worldwide. Without improvements in prevention, the burden will increase during the next 20 years because of the ageing population, especially in developing countries. Major advances have occurred in secondary prevention during the past three decades, which demonstrate the broader potential to prevent stroke. We review the main medical treatments that should be considered for most patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, and draw attention to recent developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available